Tea Lanisnik Rizner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4049152/publications.pdf

Version: 2024-02-01

150 papers

4,330 citations

36 h-index 57 g-index

151 all docs

 $\begin{array}{c} 151 \\ \text{docs citations} \end{array}$

151 times ranked

4982 citing authors

#	Article	IF	CITATIONS
1	AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer. Cancers, 2022, 14, 809.	3.7	8
2	Physiological Concentrations of Cimicifuga racemosa Extract Do Not Affect Expression of Genes Involved in Estrogen Biosynthesis and Action in Endometrial and Ovarian Cell Lines. Biomolecules, 2022, 12, 545.	4.0	1
3	Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer. Biomolecules, 2022, 12, 7.	4.0	10
4	Model Cell Lines and Tissues of Different HGSOC Subtypes Differ in Local Estrogen Biosynthesis. Cancers, 2022, 14, 2583.	3.7	5
5	Antibody Arrays Identified Cycle-Dependent Plasma Biomarker Candidates of Peritoneal Endometriosis. Journal of Personalized Medicine, 2022, 12, 852.	2.5	2
6	<i>N</i> â€Phenylâ€1,2,3,4â€tetrahydroisoquinoline: An Alternative Scaffold for the Design of 17βâ€Hydroxysteroid Dehydrogenase 1 Inhibitors. ChemMedChem, 2021, 16, 259-291.	3.2	4
7	Synthesis and evaluation of AKR1C inhibitory properties of A-ring halogenated oestrone derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 1499-1507.	5.2	3
8	Tie-2, G-CSF, and Leptin as Promising Diagnostic Biomarkers for Endometrial Cancer: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 765.	2.4	6
9	Altered Profile of E1-S Transporters in Endometrial Cancer: Lower Protein Levels of ABCG2 and OST \hat{l}^2 and Up-Regulation of SLCO1B3 Expression. International Journal of Molecular Sciences, 2021, 22, 3819.	4.1	6
10	Biomarkers of endometriosis: How far have we come and where are we going?. ZdravniÅįki Vestnik, 2021, 90, 256-265.	0.1	2
11	Aldo-Keto Reductases and Cancer Drug Resistance. Pharmacological Reviews, 2021, 73, 1150-1171.	16.0	52
12	Abstract 464: BioEndoCar: in search of new Biomarkers for Diagnosis and Prognosis of Endometrial Carcinoma., 2021,,.		0
13	AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas. Cancers, 2021, 13, 3398.	3.7	8
14	Heterocyclic androstane and estrane d-ring modified steroids: Microwave-assisted synthesis, steroid-converting enzyme inhibition, apoptosis induction, and effects on genes encoding estrogen inactivating enzymes. Journal of Steroid Biochemistry and Molecular Biology, 2021, 214, 105997.	2.5	5
15	Estrogens and the Schrödinger's Cat in the Ovarian Tumor Microenvironment. Cancers, 2021, 13, 5011.	3.7	5
16	412â€BioEndoCar: omics approaches for diagnosis and prognosis of endometrial cancer. , 2021, , .		0
17	783 AKR1C3 – a potential prognostic biomarker for patients with endometrial carcinomas. , 2021, , .		O
18	622â€The role of angiogenic factors in endometrial cancer. , 2021, , .		0

#	Article	IF	CITATIONS
19	Proteomic analysis of peritoneal fluid identified COMP and TGFBI as new candidate biomarkers for endometriosis. Scientific Reports, 2021, 11, 20870.	3.3	15
20	In the Model Cell Lines of Moderately and Poorly Differentiated Endometrial Carcinoma, Estrogens Can Be Formed via the Sulfatase Pathway. Frontiers in Molecular Biosciences, 2021, 8, 743403.	3.5	5
21	Aldo-keto reductase 1C3—Assessment as a new target for the treatment of endometriosis. Pharmacological Research, 2020, 152, 104446.	7.1	27
22	Different Culture Conditions Affect Drug Transporter Gene Expression, Ultrastructure, and Permeability of Primary Human Nasal Epithelial Cells. Pharmaceutical Research, 2020, 37, 170.	3.5	9
23	AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas. Journal of Clinical Medicine, 2020, 9, 4105.	2.4	9
24	Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells. Cancers, 2020, 12, 279.	3.7	5
25	Metabolomics for Diagnosis and Prognosis of Uterine Diseases? A Systematic Review. Journal of Personalized Medicine, 2020, 10, 294.	2.5	17
26	Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines. Journal of Pharmacy and Pharmacology, 2019, 71, 1231-1242.	2.4	23
27	Editorial: Relevance of Steroid Biosynthesis, Metabolism and Transport in Pathophysiology and Drug Discovery. Frontiers in Pharmacology, 2019, 10, 245.	3.5	1
28	Multiplex analysis of 40 cytokines do not allow separation between endometriosis patients and controls. Scientific Reports, 2019, 9, 16738.	3.3	12
29	Paramount importance of sample quality in pre-clinical and clinical researchâ€"Need for standard operating procedures (SOPs). Journal of Steroid Biochemistry and Molecular Biology, 2019, 186, 1-3.	2.5	6
30	General toxicity assessment of the novel aldose reductase inhibitor cemtirestat. Interdisciplinary Toxicology, 2019, 12, 120-128.	1.0	7
31	EP555 Biomarkers for diagnosis and prognosis of endometrial carcinoma: BioEndoCar. , 2019, , .		0
32	EP556 Decreased s-Tie2 plasma concentration in patients with endometrioid endometrial cancer. , 2019, , .		0
33	EP554â€The effects ofCimicifuga racemosaextract on endometrial and ovarian cancer cell lines. , 2019, , .		0
34	P82â€Decreased expression of ABCG2 and SLC51 Bin endometrial cancer., 2019,,.		0
35	Membrane progesterone receptors \hat{I}^2 and \hat{I}^3 have potential as prognostic biomarkers of endometrial cancer. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 303-311.	2.5	31
36	Models including plasma levels of sphingomyelins and phosphatidylcholines as diagnostic and prognostic biomarkers of endometrial cancer. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 312-321.	2.5	43

#	Article	IF	Citations
37	Detection of Aristaless-related homeobox protein in ovarian sex cord-stromal tumors. Experimental and Molecular Pathology, 2018, 104, 38-44.	2.1	1
38	It is high time to discontinue use of misidentified and contaminated cells: Guidelines for description and authentication of cell lines. Journal of Steroid Biochemistry and Molecular Biology, 2018, 182, 1-3.	2.5	6
39	Synthesis and structureâ \in activity relationships of 2- and/or 4-halogenated 13 <i>\hat{l}^2</i> - and 13 \hat{l} ±-estrone derivatives as enzyme inhibitors of estrogen biosynthesis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1271-1282.	5.2	23
40	Models including serum CA-125, BMI, cyst pathology, dysmenorrhea or dyspareunia for diagnosis of endometriosis. Biomarkers in Medicine, 2018, 12, 737-747.	1.4	5
41	Data on expression of genes involved in estrogen and progesterone action, inflammation and differentiation according to demographic, histopathological and clinical characteristics of endometrial cancer patients. Data in Brief, 2017, 12, 632-643.	1.0	5
42	Phylogenetic Studies, Gene Cluster Analysis, and Enzymatic Reaction Support Anthrahydroquinone Reduction as the Physiological Function of Fungal 17l²â€Hydroxysteroid Dehydrogenase. ChemBioChem, 2017, 18, 77-80.	2.6	13
43	STAR and AKR1B10 are down-regulated in high-grade endometrial cancer. Journal of Steroid Biochemistry and Molecular Biology, 2017, 171, 43-53.	2.5	20
44	Structural basis for inhibition of $17\hat{l}^2$ -hydroxysteroid dehydrogenases by phytoestrogens: The case of fungal $17\hat{l}^2$ -HSDcl. Journal of Steroid Biochemistry and Molecular Biology, 2017, 171, 80-93.	2.5	21
45	Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer. Gynecologic Oncology, 2017, 147, 126-132.	1.4	37
46	The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers. Frontiers in Pharmacology, 2017, 8, 346.	3.5	35
47	The Significance of the Sulfatase Pathway for Local Estrogen Formation in Endometrial Cancer. Frontiers in Pharmacology, 2017, 8, 368.	3.5	29
48	The Important Roles of Steroid Sulfatase and Sulfotransferases in Gynecological Diseases. Frontiers in Pharmacology, 2016, 7, 30.	3.5	75
49	Discovery of biomarkers for endometrial cancer: current status and prospects. Expert Review of Molecular Diagnostics, 2016, 16, 1315-1336.	3.1	56
50	Pyrithione-based ruthenium complexes as inhibitors of aldo–keto reductase 1C enzymes and anticancer agents. Dalton Transactions, 2016, 45, 11791-11800.	3.3	30
51	Recommendations for description and validation of antibodies for research use. Journal of Steroid Biochemistry and Molecular Biology, 2016, 156, 40-42.	2.5	12
52	Altered levels of acylcarnitines, phosphatidylcholines, and sphingomyelins in peritoneal fluid from ovarian endometriosis patients. Journal of Steroid Biochemistry and Molecular Biology, 2016, 159, 60-69.	2.5	52
53	Medikamentozno zdravljenje endometrioze: pregled stanja in nove možnosti zdravljenja. Zdravniški Vestnik, 2016, 85, .	0.1	0
54	Combined Liquid Chromatography–Tandem Mass Spectrometry Analysis of Progesterone Metabolites. PLoS ONE, 2015, 10, e0117984.	2.5	9

#	Article	IF	Citations
55	Ruthenium complexes as inhibitors of the aldo–keto reductases AKR1C1–1C3. Chemico-Biological Interactions, 2015, 234, 349-359.	4.0	16
56	Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2 \hat{l}_{\pm} biosynthesis and action in ovarian endometriosis tissue and in model cell lines. Chemico-Biological Interactions, 2015, 234, 320-331.	4.0	31
57	The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function. European Journal of Pharmaceutical Sciences, 2015, 69, 1-9.	4.0	106
58	Diagnostic potential of peritoneal fluid biomarkers of endometriosis. Expert Review of Molecular Diagnostics, 2015, 15, 557-580.	3.1	32
59	Panels of Cytokines and Other Secretory Proteins as Potential Biomarkers of Ovarian Endometriosis. Journal of Molecular Diagnostics, 2015, 17, 325-334.	2.8	38
60	Important roles of the AKR1C2 and SRD5A1 enzymes in progesterone metabolism in endometrial cancer model cell lines. Chemico-Biological Interactions, 2015, 234, 297-308.	4.0	31
61	The endometrial cancer cell lines Ishikawa and HEC-1A, and the control cell line HIEEC, differ in expression of estrogen biosynthetic and metabolic genes, and in androstenedione and estrone-sulfate metabolism. Chemico-Biological Interactions, 2015, 234, 309-319.	4.0	36
62	Phospholipase A2 group IIA is elevated in endometriomas but not in peritoneal fluid and serum of ovarian endometriosis patients. Gynecological Endocrinology, 2015, 31, 214-218.	1.7	6
63	The Characterization of the Human Nasal Epithelial Cell Line RPMI 2650 Under Different Culture Conditions and Their Optimization for an Appropriate in vitro Nasal Model. Pharmaceutical Research, 2015, 32, 665-679.	3.5	63
64	Increased levels of biglycan in endometriomas and peritoneal fluid samples from ovarian endometriosis patients. Gynecological Endocrinology, 2014, 30, 520-524.	1.7	12
65	Role of aldo–keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids, 2014, 79, 49-63.	1.8	159
66	Noninvasive biomarkers of endometriosis: myth or reality?. Expert Review of Molecular Diagnostics, 2014, 14, 365-385.	3.1	41
67	Synthesis and Biological Evaluation of Organoruthenium Complexes with Azole Antifungal Agents. First Crystal Structure of a Tioconazole Metal Complex. Organometallics, 2014, 33, 1594-1601.	2.3	51
68	Teaching the structure of immunoglobulins by molecular visualization and SDSâ€PAGE analysis. Biochemistry and Molecular Biology Education, 2014, 42, 152-159.	1.2	8
69	Elevated glycodelin-A concentrations in serum and peritoneal fluid of women with ovarian endometriosis. Gynecological Endocrinology, 2013, 29, 455-459.	1.7	35
70	Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Molecular and Cellular Endocrinology, 2013, 381, 124-139.	3.2	60
71	2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 $17\hat{l}^2$ -hydroxysteroid dehydrogenase (AKR1C3). European Journal of Medicinal Chemistry, 2013, 62, 89-97.	5.5	10
72	Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue. Chemico-Biological Interactions, 2013, 202, 226-233.	4.0	19

#	Article	IF	Citations
73	Progestin effects on expression of AKR1C1–AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chemico-Biological Interactions, 2013, 202, 218-225.	4.0	10
74	Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: A source of excessive hydroxy-estrogens and ROS?. Molecular and Cellular Endocrinology, 2013, 367, 74-84.	3.2	37
75	New enzymatic assay for the AKR1C enzymes. Chemico-Biological Interactions, 2013, 202, 204-209.	4.0	4
76	Introduction. Chemico-Biological Interactions, 2013, 202, 1.	4.0	0
77	Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer. Chemico-Biological Interactions, 2013, 202, 210-217.	4.0	33
78	Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines. International Journal of Molecular Medicine, 2013, 31, 717-725.	4.0	15
79	Insights into subtle conformational differences in the substrate-binding loop of fungal 17½-hydroxysteroid dehydrogenase: a combined structural and kinetic approach. Biochemical Journal, 2012, 441, 151-160.	3.7	12
80	N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo–keto reductase AKR1C3. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5948-5951.	2.2	15
81	Effects of progestins on local estradiol biosynthesis and action in the Z-12 endometriotic epithelial cell line. Journal of Steroid Biochemistry and Molecular Biology, 2012, 132, 303-310.	2.5	12
82	Selective Inhibitors of Aldo-Keto Reductases AKR1C1 and AKR1C3 Discovered by Virtual Screening of a Fragment Library. Journal of Medicinal Chemistry, 2012, 55, 7417-7424.	6.4	20
83	The role of Ala231 and Trp227 in the substrate specificities of fungal 17β-hydroxysteroid dehydrogenase and trihydroxynaphthalene reductase: Steroids versus smaller substrates. Journal of Steroid Biochemistry and Molecular Biology, 2012, 129, 92-98.	2.5	6
84	Steroid-transforming enzymes in fungi. Journal of Steroid Biochemistry and Molecular Biology, 2012, 129, 79-91.	2.5	133
85	Expression of human aldo-keto reductase 1C2 in cell lines of peritoneal endometriosis: Potential implications in metabolism of progesterone and dydrogesterone and inhibition by progestins. Journal of Steroid Biochemistry and Molecular Biology, 2012, 130, 16-25.	2.5	13
86	Steroids and microorganisms. Journal of Steroid Biochemistry and Molecular Biology, 2012, 129, 1-3.	2.5	13
87	Discovery of phosphatidylcholines and sphingomyelins as biomarkers for ovarian endometriosis. Human Reproduction, 2012, 27, 2955-2965.	0.9	108
88	Suitability of Isolated Rat Jejunum Model for Demonstration of Complete Absorption in Humans for BCS-Based Biowaiver Request. Journal of Pharmaceutical Sciences, 2012, 101, 1436-1449.	3.3	22
89	Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases. Frontiers in Pharmacology, 2012, 3, 34.	3.5	35
90	Novel Inhibitors of Trihydroxynaphthalene Reductase with Antifungal Activity Identified by Ligand-Based and Structure-Based Virtual Screening. Journal of Chemical Information and Modeling, 2011, 51, 1716-1724.	5.4	15

#	Article	IF	CITATIONS
91	Design and synthesis of substrate mimetics based on an indole scaffold: potential inhibitors of $17\hat{l}^2$ -HSD type 1. Hormone Molecular Biology and Clinical Investigation, 2011, 6, 201-209.	0.7	2
92	Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: Lower levels of CYP1B1 and increased expression of S-COMT. Molecular and Cellular Endocrinology, 2011, 331, 158-167.	3.2	59
93	Novel estrogen-related genes and potential biomarkers of ovarian endometriosis identified by differential expression analysis. Journal of Steroid Biochemistry and Molecular Biology, 2011, 125, 231-242.	2.5	37
94	Discovery of highly potent, nonsteroidal $17\hat{l}^2$ -hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening. Journal of Steroid Biochemistry and Molecular Biology, 2011, 127, 255-261.	2.5	9
95	Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids, 2011, 76, 607-615.	1.8	58
96	Synthesis and Biological Evaluation of (6- and 7-Phenyl) Coumarin Derivatives as Selective Nonsteroidal Inhibitors of $17\hat{1}^2$ -Hydroxysteroid Dehydrogenase Type 1. Journal of Medicinal Chemistry, 2011, 54, 248-261.	6.4	61
97	Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chemico-Biological Interactions, 2011, 191, 227-233.	4.0	30
98	Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines. Chemico-Biological Interactions, 2011, 191, 206-216.	4.0	48
99	Biochemical and biological evaluation of novel potent coumarin inhibitor of $17\hat{l}^2$ -HSD type 1. Chemico-Biological Interactions, 2011, 191, 60-65.	4.0	14
100	Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. Chemico-Biological Interactions, 2011, 191, 217-226.	4.0	46
101	Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4. Current Medicinal Chemistry, 2011, 18, 2554-2565.	2.4	34
102	Preparation of Recombinant Human Hydroxysteroid Dehydrogenases and Study of their Inhibitors. Scientia Pharmaceutica, 2010, 78, 592-592.	2.0	0
103	Two homologous fungal carbonyl reductases with different substrate specificities. Chemico-Biological Interactions, 2009, 178, 295-302.	4.0	5
104	Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1. Chemico-Biological Interactions, 2009, 178, 158-164.	4.0	17
105	Trihydroxynaphthalene reductase of Curvularia lunata—A target for flavonoid action?. Chemico-Biological Interactions, 2009, 178, 259-267.	4.0	18
106	Expression of $17\hat{l}^2$ -hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines. Chemico-Biological Interactions, 2009, 178, 228-233.	4.0	26
107	Simultaneous binding of coenzyme and two ligand molecules into the active site of fungal trihydroxynaphthalene reductase. Chemico-Biological Interactions, 2009, 178, 268-273.	4.0	3
108	New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. European Journal of Medicinal Chemistry, 2009, 44, 2563-2571.	5.5	26

#	Article	IF	Citations
109	Disturbed estrogen and progesterone action in ovarian endometriosis. Molecular and Cellular Endocrinology, 2009, 301, 59-64.	3.2	94
110	Mutations that affect coenzyme binding and dimer formation of fungal $17\hat{l}^2$ -hydroxysteroid dehydrogenase. Molecular and Cellular Endocrinology, 2009, 301, 47-50.	3.2	3
111	Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening. Molecular and Cellular Endocrinology, 2009, 301, 245-250.	3.2	12
112	Flavonoids and cinnamic acid derivatives as inhibitors of $17\hat{l}^2$ -hydroxysteroid dehydrogenase type 1. Molecular and Cellular Endocrinology, 2009, 301, 229-234.	3.2	48
113	Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Molecular and Cellular Endocrinology, 2009, 301, 74-82.	3.2	76
114	Estrogen metabolism and action in endometriosis. Molecular and Cellular Endocrinology, 2009, 307, 8-18.	3.2	113
115	Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: Synthesis of artificial substrate, homology modelling and initial screening. Bioorganic and Medicinal Chemistry, 2008, 16, 5881-5889.	3.0	11
116	CYP53A15 of Cochliobolus lunatus, a Target for Natural Antifungal Compounds. Journal of Medicinal Chemistry, 2008, 51, 3480-3486.	6.4	68
117	Pre-receptor regulation of the androgen receptor. Molecular and Cellular Endocrinology, 2008, 281, 1-8.	3.2	54
118	Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis. Gynecological Endocrinology, 2007, 23, 105-111.	1.7	107
119	His164 regulates accessibility to the active site in fungal 17β-hydroxysteroid dehydrogenase. Biochimie, 2007, 89, 63-71.	2.6	9
120	Rational design of novel mutants of fungal $17\hat{l}^2$ -hydroxysteroid dehydrogenase. Journal of Biotechnology, 2007, 129, 123-130.	3.8	35
121	New inhibitors of fungal $17\hat{l}^2$ -hydroxysteroid dehydrogenase based on the [1,5]-benzodiazepine scaffold. Journal of Enzyme Inhibition and Medicinal Chemistry, 2007, 22, 29-36.	5 . 2	3
122	AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Molecular and Cellular Endocrinology, 2006, 248, 126-135.	3.2	139
123	Cinnamates and cinnamamides inhibit fungal $17\hat{l}^2$ -hydroxysteroid dehydrogenase. Molecular and Cellular Endocrinology, 2006, 248, 239-241.	3.2	19
124	Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer. Molecular and Cellular Endocrinology, 2006, 248, 114-117.	3.2	33
125	Cinnamic acids as new inhibitors of $17\hat{l}^2$ -hydroxysteroid dehydrogenase type 5 (AKR1C3). Molecular and Cellular Endocrinology, 2006, 248, 233-235.	3.2	45
126	Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1. Molecular and Cellular Endocrinology, 2006, 259, 30-42.	3.2	38

#	Article	IF	Citations
127	Conformational stability of $17\hat{1}^2$ -hydroxysteroid dehydrogenase from the fungus Cochliobolus lunatus. FEBS Journal, 2006, 273, 3927-3937.	4.7	5
128	Flavonoids and cinnamic acid esters as inhibitors of fungal $17\hat{1}^2$ -hydroxysteroid dehydrogenase: A synthesis, QSAR and modelling study. Bioorganic and Medicinal Chemistry, 2006, 14, 7404-7418.	3.0	40
129	Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: New lead compounds for the development of anticancer agents. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 5170-5175.	2.2	45
130	Crystallization, X-ray diffraction analysis and phasing of $17\hat{l}^2$ -hydroxysteroid dehydrogenase from the fungusCochliobolus lunatus. Acta Crystallographica Section F: Structural Biology Communications, 2005, 61, 1032-1034.	0.7	11
131	Dimerization and enzymatic activity of fungal 17beta-hydroxysteroid dehydrogenase from the short-chain dehydrogenase/reductase superfamily. BMC Biochemistry, 2005, 6, 28.	4.4	16
132	Coenzyme specificity in fungal $17\hat{l}^2$ -hydroxysteroid dehydrogenase. Molecular and Cellular Endocrinology, 2005, 241, 80-87.	3.2	18
133	Phytoestrogens as inhibitors of fungal 17β-hydroxysteroid dehydrogenase. Steroids, 2005, 70, 626-635.	1.8	15
134	Phytoestrogens as inhibitors of fungal 17β-hydroxysteroid dehydrogenase. Steroids, 2005, 70, 694-703.	1.8	16
135	Cinnamic acid esters as potent inhibitors of fungal 17β-hydroxysteroid dehydrogenase––a model enzyme of the short-chain dehydrogenase/reductase superfamily. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3933-3936.	2.2	25
136	Evidence for 1,8-dihydroxynaphthalene melanin in three halophilic black yeasts grown under saline and non-saline conditions. FEMS Microbiology Letters, 2004, 232, 203-209.	1.8	81
137	Structure–function of human 3α-hydroxysteroid dehydrogenases: genes and proteins. Molecular and Cellular Endocrinology, 2004, 215, 63-72.	3.2	127
138	Melanin biosynthesis in the fungusCurvularia lunata(teleomorph:Cochliobolus lunatus). Canadian Journal of Microbiology, 2003, 49, 110-119.	1.7	59
139	Role of human type 3 3î±-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells. Chemico-Biological Interactions, 2003, 143-144, 401-409.	4.0	15
140	Significance of individual amino acid residues for coenzyme and substrate specificity of 1712-hydroxysteroid dehydrogenase from the fungus Cochliobolus lunatus. Chemico-Biological Interactions, 2003, 143-144, 493-501.	4.0	18
141	Human Type 3 3α-Hydroxysteroid Dehydrogenase (Aldo-Keto Reductase 1C2) and Androgen Metabolism in Prostate Cells. Endocrinology, 2003, 144, 2922-2932.	2.8	126
142	Searching for the physiological function of $17\hat{l}^2$ -hydroxysteroid dehydrogenase from the fungus Cochliobolus lunatus: studies of substrate specificity and expression analysis. Molecular and Cellular Endocrinology, 2001, 171, 193-198.	3.2	19
143	Expression of 17β-hydroxysteroid dehydrogenases in mesophilic and extremophilic yeast. Steroids, 2001, 66, 49-54.	1.8	24
144	$17\hat{l}^2$ -hydroxysteroid dehydrogenase from the fungus Cochlioboluslunatus: structural and functional aspects. Chemico-Biological Interactions, 2001, 130-132, 793-803.	4.0	20

#	Article	IF	CITATIONS
145	17î ² -Hydroxysteroid Dehydrogenase from Cochliobolus lunatus: Model Structure and Substrate Specificity. Archives of Biochemistry and Biophysics, 2000, 384, 255-262.	3.0	31
146	Characterization of fungal $17\hat{l}^2$ -hydroxysteroid dehydrogenases. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2000, 127, 53-63.	1.6	24
147	A novel $17\hat{l}^2$ -hydroxysteroid dehydrogenase in the fungus Cochliobolus lunatus: new insights into the evolution of steroid-hormone signalling. Biochemical Journal, 1999, 337, 425-431.	3.7	68
148	A novel $17\hat{l}^2$ -hydroxysteroid dehydrogenase in the fungus Cochliobolus lunatus: new insights into the evolution of steroid-hormone signalling. Biochemical Journal, 1999, 337, 425.	3.7	44
149	Purification and characterization of 17β-hydroxysteroid dehydrogenase from the filamentous fungus Cochliobolus lunatus. Journal of Steroid Biochemistry and Molecular Biology, 1996, 59, 205-214.	2.5	39
150	Steroid hormone signalling system and fungi. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1995, 112, 637-642.	1.6	31